Alport综合征患者早期使用ACEI有益

2012-04-10 范振光 国际肾脏期刊

    Alport综合征患者最终不可避免的发展为终末期肾病,而且目前没有好的治疗可以改善这一状况。       这里我们观察三个家族性Alport综合征患者使用ACEI治疗后是否可以延缓患者至透析治疗的时间以及改善患者的期望值。这些患者按照肾功能情况进行分类,其中33名合并血尿或者微量白蛋白尿、115名蛋白尿、26名肾功能受损和109名未治疗

    Alport综合征患者最终不可避免的发展为终末期肾病,而且目前没有好的治疗可以改善这一状况。       这里我们观察三个家族性Alport综合征患者使用ACEI治疗后是否可以延缓患者至透析治疗的时间以及改善患者的期望值。这些患者按照肾功能情况进行分类,其中33名合并血尿或者微量白蛋白尿、115名蛋白尿、26名肾功能受损和109名未治疗的亲戚,进行了超过20年的随访观察。结果发现未治疗的亲戚平均在22岁开始进入透析治疗;而给予ACEI治疗的患者中肾功能受损组平均在25岁进入透析治疗,蛋白尿组的则平均在40岁进入透析治疗,而合并血尿和微量白蛋白尿的患者到目前为止还未进入透析治疗阶段。同胞中的研究结果也证实了这一结果,提示相对于后期再给予或者为给与ACEI的年龄较大的同胞患者来说,较年轻的患者尽早的给予ACEI治疗可以显著延长患者13年后再进入透析治疗阶段。给予ACEI治疗的患者生命期望值则超过了平均55岁,显著高于对照组。       由此可见,对于Alport综合征患者、特别是寡症状的患者来说,尽早的给予ACEI药物治疗可以延缓其肾功能衰竭、提高患者生命的期望值,这一作用存在治疗时间早晚的依赖性。

文献来源:http://www.medlive.cn/literature/31539

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1655645, encodeId=290f16556451f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 30 09:45:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954065, encodeId=e5ed195406591, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 15 04:45:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035971, encodeId=c67420359e124, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon Nov 19 22:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430324, encodeId=1b581430324f1, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458424, encodeId=99fd145842474, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-10-30 shanyongle
  2. [GetPortalCommentsPageByObjectIdResponse(id=1655645, encodeId=290f16556451f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 30 09:45:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954065, encodeId=e5ed195406591, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 15 04:45:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035971, encodeId=c67420359e124, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon Nov 19 22:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430324, encodeId=1b581430324f1, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458424, encodeId=99fd145842474, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-12-15 仁医06
  3. [GetPortalCommentsPageByObjectIdResponse(id=1655645, encodeId=290f16556451f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 30 09:45:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954065, encodeId=e5ed195406591, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 15 04:45:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035971, encodeId=c67420359e124, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon Nov 19 22:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430324, encodeId=1b581430324f1, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458424, encodeId=99fd145842474, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
    2012-11-19 jiekemin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1655645, encodeId=290f16556451f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 30 09:45:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954065, encodeId=e5ed195406591, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 15 04:45:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035971, encodeId=c67420359e124, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon Nov 19 22:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430324, encodeId=1b581430324f1, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458424, encodeId=99fd145842474, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1655645, encodeId=290f16556451f, content=<a href='/topic/show?id=2a011829d7' target=_blank style='color:#2F92EE;'>#ACE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1829, encryptionId=2a011829d7, topicName=ACE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=635024767990, createdName=shanyongle, createdTime=Tue Oct 30 09:45:00 CST 2012, time=2012-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1954065, encodeId=e5ed195406591, content=<a href='/topic/show?id=c9a6235842' target=_blank style='color:#2F92EE;'>#Alport#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2358, encryptionId=c9a6235842, topicName=Alport)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Dec 15 04:45:00 CST 2012, time=2012-12-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2035971, encodeId=c67420359e124, content=<a href='/topic/show?id=01482345fc' target=_blank style='color:#2F92EE;'>#ALP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2345, encryptionId=01482345fc, topicName=ALP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c82369, createdName=jiekemin, createdTime=Mon Nov 19 22:45:00 CST 2012, time=2012-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430324, encodeId=1b581430324f1, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458424, encodeId=99fd145842474, content=<a href='/topic/show?id=782423592a' target=_blank style='color:#2F92EE;'>#Alport综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2359, encryptionId=782423592a, topicName=Alport综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6846069053, createdName=lancelotzzl, createdTime=Thu Apr 12 12:45:00 CST 2012, time=2012-04-12, status=1, ipAttribution=)]